LTPA2020519I1 - Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas - Google Patents

Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Info

Publication number
LTPA2020519I1
LTPA2020519I1 LTPA2020519C LTPA2020519C LTPA2020519I1 LT PA2020519 I1 LTPA2020519 I1 LT PA2020519I1 LT PA2020519 C LTPA2020519 C LT PA2020519C LT PA2020519 C LTPA2020519 C LT PA2020519C LT PA2020519 I1 LTPA2020519 I1 LT PA2020519I1
Authority
LT
Lithuania
Prior art keywords
production method
acid derivatives
boronic acid
therapeutic use
cyclic boronic
Prior art date
Application number
LTPA2020519C
Other languages
English (en)
Original Assignee
Melinta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2020519(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics, Inc. filed Critical Melinta Therapeutics, Inc.
Publication of LTPA2020519I1 publication Critical patent/LTPA2020519I1/lt
Publication of LTC3412676I2 publication Critical patent/LTC3412676I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
LTPA2020519C 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas LTC3412676I2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37229610P 2010-08-10 2010-08-10
US201161488655P 2011-05-20 2011-05-20
PCT/US2011/046957 WO2012021455A1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP11816882.2A EP2603514B1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
LTPA2020519I1 true LTPA2020519I1 (lt) 2020-08-10
LTC3412676I2 LTC3412676I2 (lt) 2022-09-12

Family

ID=45565270

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP18183968.9T LT3412676T (lt) 2010-08-10 2011-08-08 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas
LTPA2020519C LTC3412676I2 (lt) 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas
LTPA2020521C LTC3412676DI2 (lt) 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18183968.9T LT3412676T (lt) 2010-08-10 2011-08-08 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2020521C LTC3412676DI2 (lt) 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Country Status (27)

Country Link
US (10) US8680136B2 (lt)
EP (3) EP3412676B1 (lt)
JP (4) JP6266978B2 (lt)
KR (3) KR102087313B1 (lt)
CN (1) CN103180328B (lt)
AU (1) AU2011289615B2 (lt)
BR (1) BR112013003045B1 (lt)
CA (1) CA2807546C (lt)
CL (1) CL2013000399A1 (lt)
CO (1) CO6680667A2 (lt)
CY (3) CY1123208T1 (lt)
DK (2) DK2603514T3 (lt)
ES (2) ES2789177T3 (lt)
HR (1) HRP20200741T1 (lt)
HU (4) HUE048859T2 (lt)
IL (1) IL224564A (lt)
LT (3) LT3412676T (lt)
MX (1) MX348653B (lt)
MY (1) MY188960A (lt)
NO (2) NO2019013I1 (lt)
NZ (1) NZ607354A (lt)
PL (2) PL3412676T3 (lt)
PT (2) PT2603514T (lt)
RS (1) RS60310B1 (lt)
RU (1) RU2599791C2 (lt)
SG (1) SG187757A1 (lt)
WO (1) WO2012021455A1 (lt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2603514T (pt) 2010-08-10 2018-11-09 Rempex Pharmaceuticals Inc Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013122888A2 (en) * 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014052836A2 (en) 2012-09-27 2014-04-03 Dunman Paul M Methods and compositions for treating infection
AU2013355110B2 (en) * 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
CA2894892A1 (en) * 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9540389B2 (en) * 2013-05-03 2017-01-10 Microbiotix, Inc. Antimicrobial potentiators
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
LT3604316T (lt) 2014-05-05 2024-02-26 Melinta Therapeutics, Inc. Boronato druskų sintezė
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) * 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104447610A (zh) * 2014-11-21 2015-03-25 山东金城医药化工股份有限公司 高纯度头孢他啶侧链酸的制备方法
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6945452B2 (ja) 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
DK3478693T3 (da) 2016-06-30 2021-09-20 Qpex Biopharma Inc Boronsyrederivater og terapeutiske anvendelser deraf
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP3565551B1 (en) 2017-01-09 2024-03-20 Melinta Therapeutics, Inc. Methods of treating bacterial infections with a combination of vaborbactam and meropenem
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
IL301591A (en) 2017-03-06 2023-05-01 Venatorx Pharmaceuticals Inc Solid forms and combined preparations containing beta-lactamase inhibitor and their uses
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
MX2020004425A (es) * 2017-11-01 2020-08-06 Melinta Therapeutics Inc Síntesis de derivados de éster boronato y usos de estos.
CN111039965B (zh) * 2018-10-12 2020-12-01 新发药业有限公司 一种法硼巴坦的简便制备方法
WO2022182993A1 (en) * 2021-02-25 2022-09-01 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN113214302B (zh) * 2021-04-23 2022-06-24 四川大学 一种抑制金属β-内酰胺酶和/或丝氨酸β-内酰胺酶的3-取代五元环状硼酸酯衍生物

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
FR2574070B1 (fr) 1984-11-30 1987-02-27 Stam Catalyseur de prise de mortiers d'anhydrite projetes a la lance, a resistance amelioree a un stockage a temperature et humidite elevees, et utilisation d'un tel catalyseur
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
AU8140898A (en) 1997-06-13 1998-12-30 Northwestern University Inhibitors of beta-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
NZ517865A (en) 1999-09-25 2003-11-28 Smithkline Beecham P Piperazine derivatives as 5-HT1B antagonists
JP2003513890A (ja) 1999-10-28 2003-04-15 メルク エンド カムパニー インコーポレーテッド 新規なコハク酸系メタロ−β−ラクタマーゼ阻害薬およびそれの細菌感染治療での使用
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
SK2462003A3 (en) 2000-09-14 2003-09-11 Pantherix Ltd 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2002054931A2 (en) 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
KR100863667B1 (ko) 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
US8012603B2 (en) 2002-10-30 2011-09-06 Sumitomo Chemical Company, Limited Polymer compound and polymer light-emitting device using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US6936638B2 (en) 2002-12-20 2005-08-30 Migenix Corp. Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
EP1678180B1 (en) 2003-10-10 2007-08-08 Pfizer Products Incorporated Substituted 2h-[1,2,4]triazolo 4,3-a pyrazines as gsk-3 inhibitors
CA2545311C (en) 2003-11-12 2012-01-03 Phenomix Corporation Heterocyclic boronic acid compounds
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
HUE054365T2 (hu) 2005-02-16 2021-09-28 Anacor Pharmaceuticals Inc Bór-ftalidok terápiás alkalmazásra
ES2389565T3 (es) 2005-02-22 2012-10-29 Teva Pharmaceutical Industries Ltd. Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas
WO2006101779A2 (en) 2005-03-15 2006-09-28 The University Of Chicago Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
ES2373461T3 (es) 2005-12-07 2012-02-03 Basilea Pharmaceutica Ag Antibióticos útiles de monobactama.
US8168614B2 (en) 2006-02-16 2012-05-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
WO2008116813A2 (en) 2007-03-23 2008-10-02 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
MX2010005252A (es) 2007-11-13 2011-04-11 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa.
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2273882A4 (en) 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
WO2010080558A1 (en) 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
AR076667A1 (es) * 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
CA2764785C (en) 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
EP2539348A4 (en) 2010-02-26 2013-07-24 Gary Igor Dmitrienko CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
WO2011123502A1 (en) 2010-03-31 2011-10-06 Millennium Pharmaceuticals, Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
PT2603514T (pt) 2010-08-10 2018-11-09 Rempex Pharmaceuticals Inc Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
AU2012356890B2 (en) 2011-12-22 2017-06-08 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CA2862710A1 (en) 2012-01-09 2013-07-18 University Of Tromso Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2014227571B2 (en) 2013-03-15 2017-02-02 Intrexon Corporation Boron-containing diacylhydrazines
LT3604316T (lt) 2014-05-05 2024-02-26 Melinta Therapeutics, Inc. Boronato druskų sintezė
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) * 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6945452B2 (ja) 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
DK3478693T3 (da) 2016-06-30 2021-09-20 Qpex Biopharma Inc Boronsyrederivater og terapeutiske anvendelser deraf

Also Published As

Publication number Publication date
JP2021073212A (ja) 2021-05-13
US20120040932A1 (en) 2012-02-16
US9296763B2 (en) 2016-03-29
NZ607354A (en) 2015-01-30
LTPA2020521I1 (lt) 2020-08-10
EP3412676A1 (en) 2018-12-12
JP2020002178A (ja) 2020-01-09
LTC3412676I2 (lt) 2022-09-12
US20180207183A1 (en) 2018-07-26
KR101987091B1 (ko) 2019-06-10
EP2603514B1 (en) 2018-07-18
EP3666778B1 (en) 2021-11-10
PT3412676T (pt) 2020-05-19
US10183034B2 (en) 2019-01-22
JP6266978B2 (ja) 2018-01-24
US9694025B2 (en) 2017-07-04
US11684629B2 (en) 2023-06-27
CY1123208T1 (el) 2020-11-25
WO2012021455A1 (en) 2012-02-16
JP2013535502A (ja) 2013-09-12
JP7227282B2 (ja) 2023-02-21
RS60310B1 (sr) 2020-07-31
US20190076449A1 (en) 2019-03-14
CY2020019I1 (el) 2020-11-25
US20160220591A1 (en) 2016-08-04
PT2603514T (pt) 2018-11-09
PL2603514T3 (pl) 2019-04-30
ES2789177T3 (es) 2020-10-26
DK2603514T3 (en) 2018-10-29
MX348653B (es) 2017-06-21
KR20190066084A (ko) 2019-06-12
KR20200028043A (ko) 2020-03-13
US20230277571A1 (en) 2023-09-07
NO2019014I1 (no) 2019-03-28
IL224564A (en) 2017-02-28
EP2603514A4 (en) 2014-10-29
HUE048859T2 (hu) 2020-08-28
HUS1900017I1 (hu) 2019-05-28
KR20130099923A (ko) 2013-09-06
CL2013000399A1 (es) 2013-08-23
KR102205755B1 (ko) 2021-01-22
US10004758B2 (en) 2018-06-26
EP3666778A1 (en) 2020-06-17
CO6680667A2 (es) 2013-05-31
EP2603514A1 (en) 2013-06-19
US10639318B2 (en) 2020-05-05
MX2013001517A (es) 2013-04-29
JP6602742B2 (ja) 2019-11-06
CA2807546A1 (en) 2012-02-16
US20220125813A1 (en) 2022-04-28
ES2691468T3 (es) 2018-11-27
CN103180328A (zh) 2013-06-26
US8680136B2 (en) 2014-03-25
RU2013104951A (ru) 2014-09-20
US20180071325A1 (en) 2018-03-15
MY188960A (en) 2022-01-14
NO2019013I1 (no) 2019-03-28
BR112013003045B1 (pt) 2021-08-31
HRP20200741T1 (hr) 2020-10-16
US11090319B2 (en) 2021-08-17
JP2017052794A (ja) 2017-03-16
DK3412676T3 (da) 2020-05-04
CN103180328B (zh) 2016-10-26
CA2807546C (en) 2022-08-23
RU2599791C2 (ru) 2016-10-20
LTC3412676DI2 (lt) 2022-05-10
US20200222434A1 (en) 2020-07-16
US20180214465A1 (en) 2018-08-02
US20130345172A1 (en) 2013-12-26
CY2020020I2 (el) 2020-11-25
BR112013003045A2 (pt) 2016-06-14
EP3412676B1 (en) 2020-02-12
JP6854861B2 (ja) 2021-04-07
LT3412676T (lt) 2020-07-27
PL3412676T3 (pl) 2021-04-06
AU2011289615A1 (en) 2013-03-21
SG187757A1 (en) 2013-03-28
HUS1900018I1 (hu) 2019-05-28
AU2011289615B2 (en) 2015-05-07
CY2020019I2 (el) 2020-11-25
CY2020020I1 (el) 2020-11-25
US10172874B2 (en) 2019-01-08
KR102087313B1 (ko) 2020-03-11
HUE040086T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
LTPA2020519I1 (lt) Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas
EP2941247A4 (en) Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
EP2587156A4 (en) Glowplug, production method thereof and heating device
DK2934197T3 (da) Røgfrit, oralt tobaksprodukt og fremstilling deraf
SMT201500233B (it) Metodi per rilevare anticorpi anti-farmaco
DK2894151T3 (da) Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin
DK2384731T3 (da) Medicinsk behandlingsvogn
BR112012029028A2 (pt) laringoscópio, braços de laringoscópio e métodos de fabricação
BR112012032494A2 (pt) produto, utilizaçõa e método de produção de um produto
DK2819974T3 (da) Gødningsmiddel, anvendelse deraf og fremstillingsfremgangsmåde
DK2809318T3 (da) Ammoniumholdige sulfonsyre-, phosphonsyre- og carboxylsyrederivater og disses medicinske anvendelse
HUP1000366D0 (en) Novel proteins, their production process and use tereof
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
EP2881137A4 (en) MEDICAL INSTRUMENT AND METHOD FOR PRODUCING MEDICAL INSTRUMENT
PL2912039T3 (pl) Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
EP2886548A4 (en) PROCESS FOR THE PREPARATION OF A BORINIC ACID DERIVATIVE AND NEW BORIC ACID DERIVATIVE
LTC2734522I2 (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai, kaip btk inhibitoriai
CO6930059A1 (es) Formulaciones farmacéuticas y proceso de producción de formulaciones farmacéuticas
FR2966066B1 (fr) Procede de moulage en modele perdu
IT1403367B1 (it) Dispositivo elettromedicale wireless
SI3412676T1 (sl) Ciklični derivati estra borove kisline, postopek za njihovo pripravo in njihove terapevtske uporabe
PL398891A1 (pl) Sposób wytwarzania 4',5,6,7-tetrahydroksyflawanonu oraz 4',5,7,8-tetrahydroksyflawanonu
AU2012904774A0 (en) Improvements to cyclic cranked system, device and method
BRDI7101145S (pt) Configuração aplicada em jóia.